Aa
Thanks HR continued.
Well, I ain't no Russian bride but I do like my walks on the beach! Only thing is, I ain't by the beach no more...I'm working managing the nightshift over here at the Circle K? out her in Gorman? Right out by the Highway 5? You know the spot, right before you get to the Grapevine...You remember I always usedta like to wear spandex in the 80s, well and I still do! though at 5'6 and 245, I should probably try to cover up a little more, but dangit, I do love my spandex!!!! Probably too many Yoohoo's and them machine cheese nachos behing the counter, but for crissake, it gets lonely out here 3 in the mornin!
If you come out soon, we'd love to have ya! Bathroom is out right now, stupid brats firin' off cherry bombs in the toilet again, so you gotta go down to the Mickey D's for that...truckers get mad as h@ll about that but scr@w em! Well, see ya soon Revvie Boy! love to catch up!!!:))
If you come out soon, we'd love to have ya! Bathroom is out right now, stupid brats firin' off cherry bombs in the toilet again, so you gotta go down to the Mickey D's for that...truckers get mad as h@ll about that but scr@w em! Well, see ya soon Revvie Boy! love to catch up!!!:))
Life's too short...take the one you are passionate about. Where is it before I make up my mind ;)
I don't kmow much about Kaiser or CA health plans so really can't comment other than "passion" is often what makes life, life.
-- Jim
-- Jim
Id go for better pay and benes and fulfill my passion with the extra money I made.
I agree passion is important, but Im pretty practical and would take a decent but better paying, better benefits long term situation over the less pay and benefits but more passion and fun setting.
I agree passion is important, but Im pretty practical and would take a decent but better paying, better benefits long term situation over the less pay and benefits but more passion and fun setting.
MEDICAL PROFESSIONAL
Here is the abstract of the PBMc HCV RNA detection/quantification paper that you cite.
Ultrasensitive methods to measure very low levels of hepatitis C virus (HCV) RNA
in biological samples may have diagnostic and prognostic significance and be
useful to evaluate the response to antiviral treatment. A sensitive assay to
quantify HCV RNA in peripheral blood mononuclear cells (PBMCs) was developed and
validated using the iCycler iQ Detection System (Bio-Rad) coupled with TaqMan
chemistry. HCV was co-amplified with the endogenous control
glyceraldehyde-3-phosphate dehydrogenase in a multiplex reaction. Calculated PCR
amplification efficiencies for both target and control genes were used in a
mathematical model for relative quantitation of HCV RNA. A linear relationship
between input RNA and C(T) values over 6 log dilutions was observed for both
HCV- and GAPDH-specific products (R(2) > or = 0.99). As few as 1.5 IU/reaction
could be detected, with high accuracy (CV < or= 3.94%) and reproducibility (CV <
or = 2.20%). Quantitation of HCV RNA levels ranging from 10(3) to 10(7) IU/ml as
measured in 47 plasma samples was highly correlated with values obtained by the
COBAS Amplicor HCV Monitor test, v2.0 (Roche) (R(2) = 0.977). In conclusion,
this assay provides an excellent tool to determine accurately HCV kinetics in
PBMCs during antiviral therapy and to assess the long-term significance of
different patterns of response to treatment.
I placed it here so that you can see for yourself (and I checked the original full length to see if the anser is there- but NO)
WHERE IS THE QUANTITATION OR HCV KINETICS IN PBMC that they are talking about???? All they are saying is that they were measuring the plasma viral load and their method compared well with Amplicor. How much HCV RNa per PBMC?? Thats what this was all about, but no results given.??!!
You are not likely to see any commercial assays for cellular RNA for quite a while.Difficult and clinical use unclear.
Jim, the variability between commercial assays in regard to their intraassay reproducibility that you are referring to is a reality with unpleasant consequences - some do much better than others. We participated several times in comparisons of sensitivity -Eurohep I and II ( saw tremendous differences in lab performances but NGI did super, then, but I do not follow these efforts currently. When tx decisions are bases on these it is bad news.I have not looked at these aspects at NGI for a while, might want to ask our QC department how we are doing here.
Meanwhile all the considerations re the resistance power of HCV against individual component blockage apply as I discussed before.
The 5prime noncoding region is an interesting target but i do not know about efforts in this area. We sure have to be glad for this region of the virus - ootherwise we would have had no PCR for reliable detection.Even that region varies however and I remember vividly the days when I scanned this region to finally come up with one real good invariable pair of primers that made the first commercial assay for HCV and the dramatic growing of NGI possible.
Finally the Pal paper that implies a major contribution of HCV species - more than 50% - from the lymphatic system and not the liver is remarkable and could explain many of the clinical features of Hepatitis C. The news currently are not getting better. While most of these variants might not be very fit, some might sit the treatment out inthe lympahtic system and cause the high rate of relapse. On the other hand SVR is a very stable phenomenon We have to wait for an explanation for that that goes beyond speculation. A guess would be that the small amount of pseudotypes of vastly reduced fitness remaining elicits enough of an immune response to quickly control any viral spread that might occur below detectable levels.
Ultrasensitive methods to measure very low levels of hepatitis C virus (HCV) RNA
in biological samples may have diagnostic and prognostic significance and be
useful to evaluate the response to antiviral treatment. A sensitive assay to
quantify HCV RNA in peripheral blood mononuclear cells (PBMCs) was developed and
validated using the iCycler iQ Detection System (Bio-Rad) coupled with TaqMan
chemistry. HCV was co-amplified with the endogenous control
glyceraldehyde-3-phosphate dehydrogenase in a multiplex reaction. Calculated PCR
amplification efficiencies for both target and control genes were used in a
mathematical model for relative quantitation of HCV RNA. A linear relationship
between input RNA and C(T) values over 6 log dilutions was observed for both
HCV- and GAPDH-specific products (R(2) > or = 0.99). As few as 1.5 IU/reaction
could be detected, with high accuracy (CV < or= 3.94%) and reproducibility (CV <
or = 2.20%). Quantitation of HCV RNA levels ranging from 10(3) to 10(7) IU/ml as
measured in 47 plasma samples was highly correlated with values obtained by the
COBAS Amplicor HCV Monitor test, v2.0 (Roche) (R(2) = 0.977). In conclusion,
this assay provides an excellent tool to determine accurately HCV kinetics in
PBMCs during antiviral therapy and to assess the long-term significance of
different patterns of response to treatment.
I placed it here so that you can see for yourself (and I checked the original full length to see if the anser is there- but NO)
WHERE IS THE QUANTITATION OR HCV KINETICS IN PBMC that they are talking about???? All they are saying is that they were measuring the plasma viral load and their method compared well with Amplicor. How much HCV RNa per PBMC?? Thats what this was all about, but no results given.??!!
You are not likely to see any commercial assays for cellular RNA for quite a while.Difficult and clinical use unclear.
Jim, the variability between commercial assays in regard to their intraassay reproducibility that you are referring to is a reality with unpleasant consequences - some do much better than others. We participated several times in comparisons of sensitivity -Eurohep I and II ( saw tremendous differences in lab performances but NGI did super, then, but I do not follow these efforts currently. When tx decisions are bases on these it is bad news.I have not looked at these aspects at NGI for a while, might want to ask our QC department how we are doing here.
Meanwhile all the considerations re the resistance power of HCV against individual component blockage apply as I discussed before.
The 5prime noncoding region is an interesting target but i do not know about efforts in this area. We sure have to be glad for this region of the virus - ootherwise we would have had no PCR for reliable detection.Even that region varies however and I remember vividly the days when I scanned this region to finally come up with one real good invariable pair of primers that made the first commercial assay for HCV and the dramatic growing of NGI possible.
Finally the Pal paper that implies a major contribution of HCV species - more than 50% - from the lymphatic system and not the liver is remarkable and could explain many of the clinical features of Hepatitis C. The news currently are not getting better. While most of these variants might not be very fit, some might sit the treatment out inthe lympahtic system and cause the high rate of relapse. On the other hand SVR is a very stable phenomenon We have to wait for an explanation for that that goes beyond speculation. A guess would be that the small amount of pseudotypes of vastly reduced fitness remaining elicits enough of an immune response to quickly control any viral spread that might occur below detectable levels.
I had Kaiser for years. Not too bad if you really push for good care, but it takes work. I am sure you can do that Goof! Although, that said I think I picked up Hep C at Kaiser. I at least had septsis. I have heard some horror stories. I had a few GREAT doc's there that I loved though.
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
